

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): March 7, 2019

**AVALON GLOBOCARE CORP.**  
(Exact name of registrant as specified in its charter)

---

Delaware  
(State or Other Jurisdiction  
of Incorporation)

---

000-55709  
(Commission File Number)

---

47-1685128  
(IRS Employer  
Identification Number)

**4400 Route 9 South, Suite 3100, Freehold, New Jersey 07728**  
(Address of principal executive offices) (zip code)

646-762-4517  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 7.01 Regulation FD Disclosure.**

Avalon GloboCare Corp. (the “Company”) plans to present and/or distribute to the investment community and utilize at various industry and other conferences the presentation slides attached hereto as Exhibit 99.1.

The furnishing of the attached presentation is not an admission as to the materiality of any information therein. The information contained in the slides is summary information that is intended to be considered in the context of more complete information included in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the slide titled “Forward Looking Statements” in Exhibit 99.1 attached hereto.

The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the presentation attached as Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

**Item 9.01 Financial Statements and Exhibits**

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#">Company Slide Presentation</a>

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AVALON GLOBOCARE CORP.**

Dated: March 7, 2019

By: /s/ Luisa Ingargiola

Name: Luisa Ingargiola

Title: Chief Financial Officer



**AVALON**  
GLOBOCARE CORP.

# Corporate Presentation

March 2019

[www.avalon-globocare.com](http://www.avalon-globocare.com)

Nasdaq: AVCO

# Forward-Looking Statements


Certain statements contained in this presentation may constitute “forward-looking statements”, which provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (<http://www.sec.gov>). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this presentation represent the Company's views as of the date of this presentation and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this presentation.

# Corporate Overview



- Founded in 2016, Avalon GloboCare Corp. (Nasdaq: AVCO) is a leading **cell-based technology** company headquartered in New Jersey, USA
- Innovative and transformative cellular technology platforms focusing on **exosome diagnostics** (“liquid biopsy”), **regenerative therapeutics**, & **cellular immunotherapy**
- Strong proprietary **core technologies** and **intellectual properties** addressing multi-billion dollar, unmet medical niche markets worldwide
- Seamless **integration of verticals** to accelerate product development and commercialization
- Subsidiary and joint venture structure contribute to investor flexibility & R&D focus

# Avalon Timeline & Milestones



# Senior Management Team

## **Daniel Lu**

Co-founder, Chairman of the Board  
Chairman of Lu Daopei Medical Group

## **David Jin, M.D., Ph.D.**

Co-founder, CEO, President, BoD  
Co-CEO, Genexosome Technologies  
U.S. Licensed Physician; Former Professor at Weill Cornell Medical College & New York-Presbyterian Hospital; Senior Clinician-Scientist at Ansary Stem Cell Institute; Former CMO of BioTime Inc (NYSE: BTX) and its subsidiaries

## **Meng Li**

Co-founder, COO, BoD  
Former WPP Group's company executive

## **Luisa Ingargiola, CFA**

CFO, Former CFO and BoD of several U.S. Public companies

## **Professor Daopei Lu, M.D.**

*Scientific Founder*

## **Team of Our Subsidiaries**

### **Yu Zhou, M.D., Ph.D.**

Co-Founder, Co-CEO  
Genexosome Technologies Inc.

### **Steven Sukel, J.D.**

Managing Director  
Avalon RT9 Properties, LLC

### **Lucy Lu**

President  
Nanjing Epicon Biotech Co. Ltd.

*Our executive staff offer over 50 years of collective industry experience and knowledge in biotech development and healthcare management*



# Board of Directors



**Daniel Lu**

*Chairman of the Board*

*--- Healthcare Management Leadership*

**Congressman Billy Tauzin**

*Director; Former U.S. Congressman; Former President of PhRMA*

*--- Government Relations & Lobbying,  
Biotech/Pharma Leadership*

**David Jin, M.D., Ph.D.**

*Director, CEO, President*

*--- Biotech Expertise, Academic-Industry Liaison*

**Tevi Troy, Ph.D.**

*Director; Chairman of Nomination/Governance Committees  
Former Deputy Director of U.S. Human Health Services*

*--- Regulatory /HHS Expertise*

**Yancen Lu**

*Director, Chairman of Compensation Committee  
Founder and Managing Director, Puget SoundVest Group*

*--- Bio-investment / Healthcare Market Expertise*

**Steven Sanders, J.D.**

*Director, Co-Chair of Compensation Committee  
Founder of Ortoli Rosenstadt Law Firm, NYC*

*--- Legal / M&A Expertise*

**William Stilley**

*Director, Chairman of Audit Committee  
CEO, Adial Pharmaceuticals (NASDAQ: ADIL)*

*--- Wall Street Financial Expertise, Senior Pharma Executive;  
Clinical, M&A, Licencing Expertise*

## Our Scientific Founder: Professor Daopei Lu, M.D.

- Co-founded National Bone Marrow & Cord Blood Registry in China
- Founded the China Bone Marrow Donor Program
- “Father of Hematopoietic Stem Cell Transplant” in China
- Member of Chinese Academy of Engineering
- CIBMTR “Distinguished Life Contribution Award” 2016



# Our Clinical Bases in China

## Lu Daopei Hospital Network

- Beijing Lu Daopei Hospital
- Hebei Yanda Lu Daopei Hospital
- Hubei Provincial Stem Cell Bank, Wuhan Biolake
- Lu Daopei Medical Group
- Lu Daopei Hematology Research Institute, Beijing
- Over 100 affiliated hospital network (Hematopathology, FACS, FISH, Immunophenotyping, Genomics/Proteomics)
- Performed >700 cases of bone marrow transplant in 2018
- Completed >500 cases of CAR-T clinical trial as of Jan 31, 2019
- Currently ranked No.1 in hematology and bone marrow transplant service in China.



# Our Scientific & Clinical Advisory Board

**James Gajewski, M.D.** --- *Head of Advisory Board; Former MD Anderson Medical Director*

**Shahin Rafii, M.D.\*** --- *Weill Cornell; Director of Ansary Stem Cell Institute, HHMI*

**Yen-Michael Hsu, M.D., Ph.D.\*** --- *Weill Cornell; Director of cGMP Cell Engineering Facility; FACT Chief Inspector*

**Wenchun Qu, M.D., Ph.D.** --- *Mayo Clinic; Head of Regenerative Rehab Medicine*

**Peihua Peggy Lu, M.D.** --- *Executive President, Lu Daopei Hospital*

**Xin Lin, Ph.D.** --- *Tsinghua University; School of Medicine and Institute for Immunology*

\* With contractual collaborations

# Headquarters / Administrative Office



Worldwide Headquarters:  
Avalon Executive Center  
4400 Route 9 South Suite 3100  
Freehold, New Jersey, USA



# Operating Laboratories



- Weill Cornell Medicine, USA
- Co-development program with cGMP Cell Engineering Facility (Dr. Yen-Michael Hsu)
- Standardization of human stem cell derived exosomes bio-production




- Beijing Lu Daopei Hospital, China
- Exosome isolation kits manufacturing
- Exosome preparation QC/QA
- Clinical specimen collection, processing, and analysis for exosome-based liquid biopsy (oral cancer, leukemia, NASH, colon cancer)



- Nanjing BenQ Hospital, China
- Nanjing Epicon Biotech: JV between Avalon GloboCare & Nanjing Unicorn
- GMP bio-processing, bio-production of stem cells & CAR-T/immunotherapy
- Exosome bio-banking (aqueous humor exosomes)


# Paradigm Shifts in Medicine




# Overview of Exosomes (Extracellular Vesicles)



The Nobel Prize in Physiology or Medicine 2013




## Exosomes – Nano-sized Molecular Shuttles



Li Chen *et al.*, *Hepatology*, 2014 Mar;59(3):1118-29.


- Nano-vesicles, 50-150nm <sup>2</sup>
- Have a common set of membrane and cytosolic proteins
- Contain cell-type specific protein, mRNA, and miRs
- Role in transfer of RNA and protein for cell-cell interactions and signaling

- Present in biological fluids, including blood, urine and saliva
- Circulating exosomes are readily accessible and are rich sources of biomarkers that have the potential for assessing organ diseases






# Overview of Exosomes (Extracellular Vesicles)




- Exosomal biomarkers as disease-associated **diagnostics: "Liquid Biopsy"**
- Stem cell-derived exosomes as **regenerative therapeutics**
- Engineered exosomes as novel carrier for targeted therapeutics

# Liquid Biopsy

## Exosomes for personalized medicine



## What does a liquid biopsy look for?



1. Tumor sheds cancer cells into blood (**circulating tumor cells**)
2. Tumor sheds bits of cancer's genetic material into blood (**circulating tumor DNA**)
3. Parts of cancer cells get pinched off and travel into blood (**exosomes**)

# Cellular Therapeutics / CAR-T: Investment by Big Pharmas

**Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice**

Aug 30, 2017

DEALS AND IPOs

**Gilead to buy Kite Pharma in \$11.9 billion deal**

PUBLISHED MON, AUG 28 2017 - 8:27 AM EDT | UPDATED MON, AUG 28 2017 - 10:53 PM EDT

**FDA approves Yescarta from Gilead's Kite**

BY DAVID SALAZAR

October 19, 2017

Australian TGA Approves Novartis' Kymriah® CAR-T Therapy for Two Blood Cancers

December 31, 2018 By Cole Hildebr (CEO) — Leave a Comment

THE WALL STREET JOURNAL.

Jan 22, 2018

BUSINESS

**Celgene to Buy Juno Therapeutics for \$9 Billion**



The New York Times

DealBook / Business & Policy

**Bristol-Myers to Acquire Celgene in Deal Worth \$74 Billion**

Jan. 3, 2019

# Registered Cellular Therapy: U.S. Versus China



\* Data up to August 2017

# Avalon Ecosystem: Subsidiaries & Joint Ventures

*Avalon believes the future of medicine will evolve toward cell-based therapeutics and diagnostics.*

## AVALON EXOSOME TECHNOLOGY



## AVALON CELLULAR THERAPEUTICS



## AVALON HEALTHCARE FACILITY

SPV: **Avalon RT9 Properties, LLC**


## AVALON GMP FACILITY

JV: **Nanjing Epcion Biotech, Co. Ltd.**

# Subsidiaries/JV Structure Adds Flexibility & Focus

## Avalon's Success

*Subsidiaries/JV are functional  
or therapeutic area focused*





# Avalon-GT Exosome Isolation System

*Avalon-GT Exosome Isolation System*  
*A Single Proprietary Core Technology Platform which is:*  
***Versatile, Highly Scalable, Enhanced Purity***

## **Advantages Over Traditional Ultra-Centrifugation (UC) Methodology**

- Fast turn-around time (within minutes) vs. traditional UC (1-2 days)
- High purification rate of exosomes; over 95%
- Proprietary ultra-filtration mechanism; least harmful to exosome products
- Highly scalable volume of ultra-filtration concentrators available:

- Isolate exosomes from microliters of blood, serum, saliva, urine →

Diagnostics  
“Liquid Biopsy”

- Isolate exosomes from large-volume of stem cell culture media →

Regenerative  
Therapeutics



# Avalon-GT's Operational / Commercial Program

1

**Exosome Isolation  
System as  
Research Tool**

(Ready for Commercialization)

2

**"Liquid Biopsy" to  
Identify Disease-Specific  
Exosomal Biomarkers**

(Accademia-Industry  
Co-Development Programs)

3

**Clinical-Grade  
Stem Cell Derived  
Exosome Bio-production  
for Regenerative  
Applications**

(In-House Development;  
Industry-Industry Co-  
Development)

# Avalon-GT's Operational Program

1

1

Exosome Isolation  
System as  
Research Tool

(Ready for Commercialization)

## *In commercialization stage*

2019 Q1:

- Scale up manufacturing and increase distributorship



GET™ "ONE Drop" Exosome Isolation Kit (for Serum/Plasma)

GET™ Exosome Isolation Kit (for Cell Culture Medium)

GET™ Exosome Isolation Kit (for Stem Cell)

## 2

**"Liquid Biopsy" to  
Identify Disease-Specific  
Exosomal Biomarkers**

(Accademia-Industry  
Co-Development Programs)

### Criteria

- Unmet medical need with global market value >\$1B
- Prestigious clinical partners with authoritative Pis
- Abundant bio-specimens & patient population
- Opportunities for high-impact IPs & Publications
- Preferably as "Companion Diagnostics" development

# Avalon-GT's Operational Program

2

2

"Liquid Biopsy" to Identify Disease-Specific Exosomal Biomarkers

(Accademia-Industry Co-Development Programs)

Current Clinical Programs	Novel Exosomal Biomarker	Clinical Partners	Pub.	IP
<b>Oral Cancer</b>	✓	Weill Cornell Beijing Stomatology Hospital	✓	China PCT ✓
<b>NASH*</b>	✓	Weill Cornell, NYPH, UCSD Beijing Friendship Hospital		Pending ✓
<b>Leukemia MRD**</b>	✓	Weill Cornell, NYPH Lu Daopei Hospital		
<b>Colorectal Cancer</b>	✓	Weill Cornell, NYPH Arbele Ltd.		
<b>Macular Degeneration</b>	✓	Nanjing BenQ Hospital, GT Aqueous Humor Biobank, Jiangsu Provincial People's Hospital		

\* Nonalcoholic Steatohepatitis    \*\* Minimal Residual Disease

# Avalon-GT's Operational Program

2

## Avalon-GT Diagnostic Product Development Pipeline Exosome-Based Liquid Biopsy

Indication	Research	Development	Clinical Validation	Commercialiation
<b>Oral Cancer</b>	Exosomal Biomarker identified: miR-185		Completion By 2019 Q4	Expectation: 2020 Q2 China 2010 Q4 USA
<b>NASH</b>	Exosomal Biomarker identified	Multiple clinical sites in US & China	Initiation by 2019 Q2	
<b>Leukemia MRD</b>	Exosomal Biomarker identified	Co-development with Weill Cornell & LDP Hospital	Initiation by 2019 Q2	
<b>Colorectal CA</b>	Exosomal Biomarker identified	Co-development with Arbele	Initiation by 2019 Q2	
<b>Macular Degen.</b>	Exosomal Biomarker identified	As part of aqueous humor bio-bank (Nanjing Epicon)	Initiation by 2019 Q3	

# Avalon-GT's Liquid Biopsy Program - Oral Cancer

## Liquid Biopsy (Exosome Diagnostics)



**Oral Leukoplakia → Oral Cancer**

(pre-cancerous state)

(malignant)



Relative level of saliva-based exosomal miR-185 (cancer suppressor)

# Avalon-GT's Liquid Biopsy Program - Oral Cancer

## Liquid Biopsy (Exosome Diagnostics)



**Oral Leukoplakia → Oral Cancer**

(pre-cancerous state)


(malignant)



Relative level of saliva-based exosomal miR-185 (cancer suppressor)

## Exosome Therapeutics

bio-engineered MSC stem cells over-expressing miR-185



**"bio-factory" for exosomal miR-185**

exosomes carrying miR-185

exosomes isolation

apply to oral leukoplakia group

apply to oral cancer group

**Results: Exosomal miR-185 deters progression of oral leukoplakia to oral cancer, as well as reversal of oral cancer\***

AVA-201  
(MSC-Exo-miR185)

\* manuscripts submitted; publication pending

# Avalon-GT's Program - Oral Cancer

Nasdaq

AVA-201  
(MSC-Exo-miR185)

**Avalon GloboCare and its Subsidiary Genexosome Technologies Announce Discovery and Development of World's First Saliva-Based Exosomal Biomarker "miR-185" as Dual Diagnostic and Therapeutic Target for Oral Cancer**


28-01-2019

*Study Accepted as Poster Presentation at the 8<sup>th</sup> Annual Meeting of the International Society for Extracellular Vesicles (ISEV 2019)*

*Publication of PCT Patent Application Covering a Method for Preventing and Treating Oral Cancer with Extracellular Vesicles (Exosomes) Carrying miR-185*



# Avalon-GT's Exosome Therapeutic Pipeline



# Avalon-GT's Operational Program

3

3

Clinical-Grade  
Stem Cell Derived  
Exosome Bio-production  
for Regenerative  
Applications

(In-House Development;  
Industry-Industry Co-  
Development)

## Standardization/ Accreditation:



*Completion of standardization SOP by end of 2019 Q1;  
Initiation of strategic product co-development; Acceleration of commercialization*

### Standardization Strategic Partnership

- Weill Cornell Medicine
- New York-Presbyterian Hospital
- cGMP Cell Engineering Facility

### Clinical-Grade, Stem Cell-Derived Exosomes from:

- Mesenchymal Stem Cell (MSC)
- Endothelial Progenitor Cell (EPC)
- Hematopoietic Stem Cell (HPSC)
- Endothelial Cell (EC, HUVEC)
- Other Cell Types

### Stem Cell Exosome Products Strategic Partnership

#### **Personal Care / Topical**

- Hair Restoration
- Cosmeceuticals/Skincare
- Anti-Scar
- Anti-Wrinkle
- Diabetic Foot Ulcer
- Decubitus Ulcer
- Wound Care Products

#### **IV / Injectables**

- Anti-Fibrosis (Liver, Lung)

# Avalon Subsidiary: Avactis Biosciences



- AVACTIS acronym: **A**VA**l**on **C**ellular **T**herapy **I**ntegrated **S**ystem
- A wholly owned subsidiary of Avalon GloboCare Corp.
- Avactis Biosciences is dedicated to integrate and optimize global scientific and clinical resources in cellular therapy, including stem cells and re-engineered T/NK cells.
- State & date of incorporation: Nevada, July 2018

# Avalon/Avactis – Arbele Joint Venture

**AP** AP NEWS

Top Stories Topics Video Listen

## Avalon GloboCare Establishes Joint Venture with Arbele Limited to Co-develop Next-Generation Multi-Targeted CAR-T Cellular Immunotherapy

Avalon GloboCare Corp. January 3, 2019



*Arbele Corp., Seattle*



*Arbele Limited, Hong Kong Science & Technology Park*

# Avalon/Avactis Business Focus: Cellular Therapeutics

**Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice**

Aug 30, 2017

**Gilead to buy Kite Pharma in \$11.9 billion deal**

PUBLISHED MON, AUG 28 2017 - 8:27 AM EDT | UPDATED MON, AUG 28 2017 - 10:50 PM EDT

**FDA approves Yescarta from Gilead's Kite**

BY DAVID SALAZAR

October 19, 2017

**Problems with first generation CAR-T technology:**

- *Single target*
- *Viral vector (limited package capacity)*
- *Cytokine release syndrome (CRS)*
- *Neurotoxicity*

# Avalon/Avactis – Arbele Joint Venture

---

## Avalon GloboCare Announces Filing of Provisional Patent Applications for AVA-101, a Novel Transposon-Based, Multi-Targeted CAR-T Therapy

*AVA-101 designed to enhance efficacy and overcome safety challenges of current CAR-T immune-oncology therapeutics*

*AVA-101 represents a first-in-class transposon-based Chimeric Antigen Receptor (CAR) system targeting both CD19 and CD22 on tumor cells, enabling a flexible, combinational and cost-effective cancer immunotherapy*

---

*PR on January 26, 2019*

### Avalon's next generation CAR-T technology:

- *Multiple targets (increased efficacy)*
- *Applicable in multiple cell types: CAR-T, CAR-NK, universal CAR-T/-NK*
- *Transposon-engineered, non-viral vector (expanded package)*
- *"Safety-switch" control mechanism; reduced cytokine release syndrome & neurotoxicity*
- *Faster bio-production*
- *Strong intellectual properties*

# Avalon/Avactis Cellular Therapy Platform

## Avalon Integrates Key Verticals for Successful Cellular Therapy Program

### UPSTREAM

- Proprietary CAR constructs
- Novel, proprietary therapeutic targets
- Non-viral vector; transposon technology
- “Safety-switch” mechanism
- Multiple therapeutic targets
- **JV: AVAR BioTherapeutics**  
*(incorporation in progress)*

### MIDSTREAM

- Fast turn-around time
- Efficient cell expansion
- Standardization in bio-production process
- cGMP, FACT
- Stringent QC/QA
- Logistic cold-chain
- **JV: Epicon Biotech (GMP facility in Nanjing)**

### DOWNSTREAM

- Clinical protocol, IRB
- Experienced clinical team
- Leukapheresis
- Lymphodepletion chemo
- Bridging to transplants
- CAR-T/-NK Biobanks
- **Clinical base: Lu Daopei Hospital (performed over 500 cases of CAR-T therapies)**

# Avalon/Avactis Cellular Therapy Platform

## *Joint Venture Between Avalon/Avactis and Arbele Limited*

### *For Hematologic Malignancies*

- Design and bio-production of non-viral vector (transposon-based) transduced CAR-T immunotherapy for B-ALL, Lymphoma, and Multiple Myeloma
- Targets: CD19, CD22, CD123, Dual CAR
- Co-owned intellectual properties
- This project will subsequently move on to clinical trial(s) at Hebei Yanda Lu Daopei Hospital and Beijing Lu Daopei Hospital after target validation processes

### *For Solid Tumors*

- Design and bio-production of non-viral vector (transposon-based) transduced CAR-T immunotherapy for Gastric, Lung, and Liver cancers
- Target: Human Cadherin 17 and others
- This project will subsequently move on to clinical trial(s) at Avactis' affiliated cancer centers in US and China



# Avalon Therapeutic Pipeline

Program	Pre-clinical	Design control / IND enabling	Clinical Development			Regulatory Pathway
			Safety	Efficacy	Pivotal	
<b>AVA-101</b> (CD19xCD22 CAR-T)	B-ALL, NHL	Initiation by 2019 Q2	Initiation by 2020 Q1			US FDA & China FDA

# Avalon Therapeutic Pipeline



Program	Pre-clinical	Design control / IND enabling	Clinical Development			Regulatory Pathway
			Safety	Efficacy	Pivotal	
<b>AVA-101</b> (CD19xCD22 CAR-T)	B-ALL, NHL	Initiation by 2019 Q2	Initiation by 2020 Q1			US FDA & China FDA
<b>AVA-201</b> (MSC-Exo-miR185)	Oral Leukoplakia, Oral Cancer		Initiation by 2019 Q2			US FDA & China FDA
<b>AVA-202</b> (Angiogenic Exosome)	Ischemic / Vascular Diseases	Initiation by 2019 Q2				US FDA & China FDA
<b>AVA-203</b> (MSC-Exosome)	Liver / Lung Fibrosis	Initiation by 2019 Q2				US FDA & China FDA

# Avalon's Near-Term Milestones & Investment Highlights: GT

- **Exosome isolation system / research tools (commercialization stage):**
  - 2019-Q1: Add commercial, academic, and R&D customers
  - 2019-Q1: Add distribution partners (USA, China)
  - 2019-Q1: Scale up manufacturing (USA, China)
- **Bio-production of clinical-grade stem cell-derived exosomes:**
  - 2019-Q1: Complete standardization process (co-development with Weill Cornell)
  - 2019-Q1: IP Filings; publication of SOPs
  - 2019-Q2: Complete development of clinical-grade exosomes for regenerative products and therapeutics by partnering with pharma/biotech/personal care product companies, as well as in-house development  
SCOPE: hair growth, skincare, anti-scar, anti-wrinkle, diabetic/decubitus ulcer wound healing ...etc
- **Exosome-based liquid biopsy:**
  - 2019-Q1: Complete exosomal miR-185 pilot studies (oral leukoplakia/oral cancer)
  - 2019-Q1: IP filings; submit publications
  - 2019-Q2: Presentation of pilot studies (oral leukoplakia/oral cancer) at 2019 ISEV conference
  - 2019-Q2: Initiate exosomal biomarker studies for NASH, Leukemia MRD, colorectal cancer
  - 2019-Q3: Initiate aqueous humor exosome biobank operation (at JV Nanjing Epicon GMP facility)
  - 2019-Q4: Complete exosomal miR-185 (oral leukoplakia/oral cancer) clinical development
    - Filing for China FDA/NMPA medical device registration
    - Filing US FDA 510(K) application

## Avalon's Near-Term Milestones & Investment Highlights: Avactis

- 2019-Q1: Complete USPTO provisional patent filing of AVA-101 (a novel, transposon-based, bispecific (CD19 X CD22) CAR-T with “safety switch” control system); JV with Arbele Limited
- 2019-Q2: Disease model testing for AVA-101; complete validation testing
- 2019-Q3: Begin bio-production of AVA-101 CAR-T (at JV Nanjing Epicon GMP facility)
- 2019-Q3: Start principal investigator initiated first-in-human clinical study of AVA-101 (at Beijing Lu Daopei Hospital; PI: Dr. Peihua Lu); scope: B-ALL and lymphoma
- 2019-Q4: Submit PI-initiated clinical study data to CFDA
- 2019-Q4: Obtain regulatory approval to start AVA-101 multi-center Phase I/II clinical trials in China



# Equity Snapshot

Avalon GloboCare Corp.	
Exchange	NASDAQ: AVCO
Recent Stock Price*	\$3.57
Shares Outstanding**	74,310,751
Market Capitalization	\$265.3M
Average Volume*	715K
Float	21.3M shares
Insider Ownership	71.3%
Fiscal Year-End	December 31, 2018

\* As of March 5, 2019

\*\* As of January 15, 2019 in latest S3



**AVALON**  
GLOBOCARE CORP.

Nasdaq: AVCO

Contact:

David Jin, MD, PhD

President & CEO

Email: [david@avalon-globocare.com](mailto:david@avalon-globocare.com)